Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Robin

Showing results (1-10 of 298) with videos related to

Pageof 30
Sort By:
Leukemia|July 15, 2020
Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?Marie Robin, Pierre Fenaux
Bulletin Du Cancer|July 29, 2023
[Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes]Viviane Gournay, Marie Robin
Best Practice & Research. Clinical Haematology|May 29, 2020
Contemporary treatment approaches to CMML - Is allogeneic HCT the only cure?Marie Robin, Raphael Itzykson
Frontiers in Oncology|June 20, 2019
Should a Multigene Signature be Used in all Luminal Early Breast CancersNawale Hajjaji, Yves Marie Robin, Jacques Bonneterre
La Revue Du Praticien|February 14, 2009
[Long-term follow-up after hematopoietic stem cell transplantation]Marie Robin, Régis Peffault de Latour, Gérard Socié
Bulletin Du Cancer|February 4, 2006
[Monoclonal antibodies for lymphomas and leukemias in 2005]Régis Peffault de Latour, Marie Robin, Jacques Olivier Bay
Critical Reviews in Oncology/Hematology|November 9, 2010
Angiosarcoma: state of the art and perspectivesNicolas Penel, Sandrine Marréaud, Yves-Marie Robin, et al.
Bulletin Du Cancer|October 10, 2018
[Dermatofibrosarcoma: Management]Nicolas Penel, Sophie El Bedoui, Yves-Marie Robin, et al.
Cancer Immunology, Immunotherapy : CII|May 13, 2005
Targeted immunotherapy in acute myeloblastic leukemia: from animals to humansMarie Robin, Marie-Hélène Schlageter, Christine Chomienne, et al.
Critical Reviews in Oncology/Hematology|April 23, 2020
Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignanciesNicolas Penel, Loïc Lebellec, Jean-Yves Blay, et al.
Pageof 30

Showing results (1-10 of 298) with videos related to

Sort By:
Pageof 30
Leukemia|July 15, 2020
Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?Marie Robin, Pierre Fenaux
Bulletin Du Cancer|July 29, 2023
[Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes]Viviane Gournay, Marie Robin
Best Practice & Research. Clinical Haematology|May 29, 2020
Contemporary treatment approaches to CMML - Is allogeneic HCT the only cure?Marie Robin, Raphael Itzykson
Frontiers in Oncology|June 20, 2019
Should a Multigene Signature be Used in all Luminal Early Breast CancersNawale Hajjaji, Yves Marie Robin, Jacques Bonneterre
La Revue Du Praticien|February 14, 2009
[Long-term follow-up after hematopoietic stem cell transplantation]Marie Robin, Régis Peffault de Latour, Gérard Socié
Bulletin Du Cancer|February 4, 2006
[Monoclonal antibodies for lymphomas and leukemias in 2005]Régis Peffault de Latour, Marie Robin, Jacques Olivier Bay
Critical Reviews in Oncology/Hematology|November 9, 2010
Angiosarcoma: state of the art and perspectivesNicolas Penel, Sandrine Marréaud, Yves-Marie Robin, et al.
Bulletin Du Cancer|October 10, 2018
[Dermatofibrosarcoma: Management]Nicolas Penel, Sophie El Bedoui, Yves-Marie Robin, et al.
Cancer Immunology, Immunotherapy : CII|May 13, 2005
Targeted immunotherapy in acute myeloblastic leukemia: from animals to humansMarie Robin, Marie-Hélène Schlageter, Christine Chomienne, et al.
Critical Reviews in Oncology/Hematology|April 23, 2020
Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignanciesNicolas Penel, Loïc Lebellec, Jean-Yves Blay, et al.
Pageof 30